CVRx, Inc. develops an implantable technology for the treatment of high blood pressure/hypertension and heart failure patients. It offers BAROSTIM NEO, a neuro-modulation therapy that triggers the body''s natural reflex to regulate blood pressure and the underlying causes of the progression of heart failure, which is delivered through a long-lasting implant system, and customized to each patient''s individual therapy needs. The company serves patients and healthcare professionals. CVRx, Inc. was incorporated in 2000 and is based in Minneapolis, Minnesota. It has operations in the United States, the United Kingdom, the Netherlands, Italy, Germany, and internationally. GBP/USD in focus ahead of FED and BOE meetings Both the Federal Reserve and Bank of England will deliver their updated monetary policies this week, with GBP/USD likely to experience increased momentum.
24 hours ago
The markets expect FOMC to cut but outlook in 2025 is less certainMarkets expect a 25bp rate cut at the FOMC meeting on December 18, 2024, amid strong U.S. economic data. However, the outlook for 2025 remains uncertain as inflation and growth trends evolve.
12:20, 17 December 2024
Pi Network coin price prediction: Third party price targetDiscover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
12:20, 13 December 2024
Projected US interest rates in 5 years: Third party round upAs the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
08:24, 13 December 2024